Clinical Trials Browser

Hodgkin Disease, Lymphoma, B-Cell

Lymphoma, Mantle-Cell

Recurrence, Lymphoma, Mantle-Cell

Multiple Myeloma

Lymphoma, B-Cell, Marginal Zone

Multiple Myeloma

Multiple Myeloma

Lymphoma, Follicular

Multiple Myeloma

Multiple Myeloma, Neoplasms, Plasma Cell

Multiple Myeloma

Multiple Myeloma

Heart Failure, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating, Cardiotoxicity

Amyloidosis, Multiple Myeloma, Neoplasm, Residual

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

Multiple Myeloma

Multiple Myeloma

Lymphoma, B-Cell, Marginal Zone

Lymphoma, Large B-Cell, Diffuse

Leukemia, Plasma Cell, Multiple Myeloma

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Multiple Myeloma, Neoplasms, Peripheral Nervous System Diseases

Multiple Myeloma

Lymphoma, B-Cell, Marginal Zone

Multiple Myeloma, Neoplasms

Multiple Myeloma

Multiple Myeloma

Lymphoma, B-Cell

Lymphoma, Large B-Cell, Diffuse

Multiple Myeloma

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Lymphoma, Non-Hodgkin

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

Recurrence, Lymphoma, Large B-Cell, Diffuse

Multiple Myeloma

Neoplasms, Plasma Cell

Multiple Myeloma, Neoplasm, Residual

Lymphoma, Mantle-Cell

Lymphoma, Follicular

Lymphoma, Large B-Cell, Diffuse

Multiple Myeloma

Lymphoma, Mantle-Cell

Lymphoma, Large B-Cell, Diffuse

Multiple Myeloma

Lymphoma, B-Cell, Marginal Zone

Multiple Myeloma

Lymphoma, Large B-Cell, Diffuse

Lymphoma, Lymphoma, Follicular

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

Clinical Trials

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma

ECLAT

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL

HEME-18

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

FASTER

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

MASTER-2

Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma

HO170DLBCL

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

HD10/DSMMXX

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

UltraFrailMM

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

VRd MM Fibrate

ERd Combination Treatment in Newly Diagnosed Multiple Myeloma

Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

IFM2021-01

Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

Pola-ZR2P in Previously Untreated DLBCL

SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

REPIFIR

MTR²

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial

Risk Stratification and MRD-driven Maintenance for MM After ASCT

V-MIND

MorningLyte

Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL

HOVON174MM

ZGR

The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma

TALTEC

Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma

Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

REFRACT

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma